Synta stops melanoma drug trials due to serious safety risks

March 2, 2009

National report - Synta Pharmaceuticals has stopped drug trials for a melanoma drug due to serious safety issues, Forbes.com reports.

National report

- Synta Pharmaceuticals has stopped drug trials for a melanoma drug due to serious safety issues, Forbes.com reports.

The drug, called elesclomol, was supposed to work by increasing oxidative stress, which would cause cancer cells to self-destruct. However, during the trials there was a higher death rate among patients taking the experimental drug, according to Forbes.